The use of the corticosteroids (the compounds are used for therapeutic purposes, in order to suppress the inflammation as in asthma, or pain), since they are administered during the first week of admission, you can to reduce by up to 50 per cent of the mortality from Covid-19. Already, the use of the antibioticssuch as lopinavir and ritonavir, they are not associated with a higher rate of survival. These are, for the time being, the two conclusions can be drawn from a study carried out by researchers from the Spanish Society of Hospital Pharmacy (SEFH).
The Sierra, the coordinator of the SEFH, she explains that this is a “work-a lot of calls”, that is, the doctors have not been “instructed” to make certain decisions based on the research, which was to take place, the results are only a result of the data collection to be taken on a daily basis The 174 hospitals. “Of course, that the whole of the scientific community and expects that these findings will serve to promote research into treatments and clinical trials,” said The Sierra’s.
This is the first work to be published in the Annals of Internal Medicine, tracked the progress of the 5.386 patients you have now completed the treatment, making it one of the largest studies carried out to date,” explains El país. Among the most serious, and in need of hospitalization, the mortality rate was 17.8 percent at the end of the 28 days.
It was also a 30% reduction in the mortality rate in connection with the use of the Nonethat belongs to a group of drugs called for the clot-busting drugs. The results obtained in the fight against the Covid-19 may be related to the fact that it’s Recommended to be used in order to prevent the blockage of blood vessels by blood clots (such as in the case of stroke, one of the observed effects on infection by the Covid-19. In may, a group from the National Center for Research in Cardiovascular, led by Valentin Fuster, has published a new study on the benefits of anticoagulant therapy in hospitalized patients with the new coronavirus.
One of the conclusions of the study are to hydroxychloroquinethe medicine against malaria, with a protective effect against the disease,” according to the SEFH is, in spite of the World Health Organization this week, has decided to suspend, for the second time, in the clinical trials of hydroxychloroquine in the treatment for the new coronavirus.
WHO came to believe that the drug in question reduces the mortality rate in patients infected with the Covid-19,” said Ana Maria Henao Restrepo, a member of the emergency on the health of the world health organization. The coordinator said that the WHO decided to suspend the trial of hydroxychloroquine, which are based on the results of the test Recovery in the United Kingdom, that “he did not show any benefit from the use of the new drug against a viral disease”.
Results The Sierra, to the contrary, based on the study of the SEFH. “In the Recovery, the researchers used higher doses of hydroxychloroquine than those used in the centres of the spaniards,” adding that in 10 years, “some of the patients had received at 9.6 ounces, while the average in Spain is 3.6 grams in seven days.” And it concludes that the medicine is an anti-inflammatory, very reasonable. In fact, the reasons that led to the WHO to enable the use of this product, has been widely questioned.
In this study, which reflects that it has been practised in the hospitals and in Spanish, arrives at another conclusion: “as Well as the flu, the anti-virals don’t seem to workit, “ says Sierra. The two antivirals such as lopinavir, and ritonavirque, which are used against HIV, continuing, however, to be investigated by the WHO, in an attempt to find a solution to the battle of the Covid-19.
The same is true for the combination of the hydroxychloroquine and azithromycin (a antibiotic), which does not seem to be beneficial to the data of the SEFH. At the beginning of the epidemic, many of the antibiotics that have been used to prevent the development of pneumonia, but later they were dropped when they came to the conclusion that they were not effective. The WHO has recommended, yet, to reduce as far as possible, its use to prevent resistance to superbugs.